IE
ATYR

Israel Englander’s aTyr Pharma ATYR Stock Holding History

Israel Englander’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50,000
Closed -$254K – 6548
2025
Q2 		$254K Buy
+50,000
New +$197K ﹤0.01% 5259

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Israel Englander's ATYR Position: Q2 2026 in Review

Israel Englander reduced its aTyr Pharma (ATYR) stake by 60% in Q2 2026, selling an estimated $644K and leaving 656,051 shares worth $392K. The position accounts for ﹤0.01% of the portfolio, ranked #4947.

Israel Englander first reported a position in ATYR in Q4 2015 and has held it in 25 quarters since. The position peaked at $8.11M in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Israel Englander held 656,051 shares of aTyr Pharma worth $392K as of Q2 2026.
  • Israel Englander sold 985,195 aTyr Pharma shares in Q2 2026, an estimated $644K.
  • aTyr Pharma made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4947 holding.
  • Israel Englander first reported a position in aTyr Pharma in Q4 2015 and has held it in 25 quarters since.
  • Israel Englander's aTyr Pharma position peaked at $8.11M in Q2 2025.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.